Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report

By
Federica Gigli
Valentina Fabiola Sangiorgio
Valentina Tabanelli
Giuliana Gregato
Francesco Bertolini
Alessio Maria Edoardo Maraglino
Simona Sammassimo
Rocco Pastano
Enrico Derenzini
Corrado Tarella
July 2, 2026
0 min

Frontiers In Immunology

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Hematology
- Oncology
#2

Mayo Clinic Cancer Center

Rochester, Minnesota
Key Differentiators
- Hematology
- Oncology
#3

Harvard Medical School

Boston, Massachusetts
Key Differentiators
- Hematology
- Oncology

Original Source(s)

Frontiers In Immunology

Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report

by Federica Gigli, Valentina Fabiola Sangiorgio, Valentina Tabanelli, Giuliana Gregato, Francesco Bertolini, Alessio Maria Edoardo Maraglino, Simona Sammassimo, Rocco Pastano, Enrico Derenzini, Corrado Tarella
July 2, 2026

Related Content

Dana-Farber

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.